Bob Schwartz is a patent litigator whose practice focuses on life sciences litigation, inter partes review (IPR), and post-grant review (PGR). The technology areas Bob has experience in include vaccines, fusion proteins, immunoglobulins, siRNA, DNA sequencing, and small-molecule pharmaceuticals. Prior to becoming an attorney, he was a professor at the Albert Einstein College of Medicine, where he was a principal investigator conducting grant-funded biomedical research. He also formerly served as a staff scientist at Children's Hospital Oakland Research Institute (CHORI). Bob leads Venable’s BiologicsHQ where he has published more than 100 articles and blog posts related to biologics and biosimilars.